Pasithea Therapeutics Receives FDA Fast Track Designation

Pasithea Therapeutics has been granted Fast Track Designation by the FDA for its investigational drug PAS-004, intended for the treatment of plexiform neurofibromas associated with Neurofibromatosis Type 1 (NF1). This designation is reserved for drugs that treat serious conditions and fill an unmet medical need, potentially expediting the development and review process. PAS-004 aims to address significant morbidity caused by these tumors. The Fast Track status signifies the FDA's recognition of the potential of PAS-004 to offer a meaningful therapeutic option for patients suffering from this challenging condition.